Back to search
FDAFDA · Food and drugs·Recall number D-0700-2026

Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6949-61

Published July 29, 2026 · Recall initiated: July 13, 2026

Summary

FDA records drug Class II recall D-0700-2026, published July 29, 2026 and initiated July 13, 2026. Recalling firm: Major Pharmaceuticals; Status: Ongoing; Reported quantity: N/A; Lot: Lot#: N02212, Exp. Date 07/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOTHYROXINE SODIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOTHYROXINE SODIUM
Manufacturer
Major Pharmaceuticals
Distributor
Nationwide in the USA.
Lot
Lot#: N02212, Exp. Date 07/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6949-61 recalled?

Yes. FDA published recall D-0700-2026 on July 29, 2026. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOTHYROXINE SODIUM.